STOCK TITAN
  1. Home
  2. BRPA

Big Rock partners Acquisition (BRPA) Stock Price, News & Analysis

BRPA
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
61 183 sessions, May 6, 2020 to May 24, 2021
Largest daily move
+88% close of May 20, 2021
1-year change
+119% closing prices, May 6, 2020 to May 24, 2021

Company Description

BRPA has gained 119.0% over the past year. The last closing price was $24.25.

This page collects what Stock Titan holds for BRPA, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
+119%
Performance 1 year
-
Market Cap
-
Shares outstanding

Big Rock partners Acquisition (BRPA) closed at $24.25 on May 24, 2021. Over the past 12 months, the price has gained 119.0%.

See what a $1,000 investment in BRPA would be worth today

BRPA Metrics & Rankings

Month to date
-37.3%
View ranking
YTD
-0.6%
View ranking

Price returns through May 24, 2021. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
—

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

acquisition
-11.88%

Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

acquisition
-5.39%

NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

covid-19
+13.50%

Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

clinical trial covid-19
-14.15%

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

+3.14%

Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal

acquisition
+12.51%

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

clinical trial covid-19
+36.33%

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure

clinical trial covid-19
+8.33%

Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination

acquisition
+2.26%

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Big Rock partners Acquisition has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include acquisition, covid-19, clinical trial. View all BRPA news →

SEC Filings

View All

No SEC filings available for BRPA.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the current quoted price of Big Rock partners Acquisition (BRPA)?

The current quoted price of Big Rock partners Acquisition (BRPA) is $24.25 as of May 24, 2021.